Peter Kiener

USPTO Granted Patents = 16 (Patent Applications = 24)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 4.7

ph-index = 6

Forward Citations = 135(Granted Patents)

Company Filing History:

The Feinstein Institute for Medical Research

where one patent can have more than one assignee

Years Active: 2009-2020

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10526381 - Multivalent and monovalent multispecific complexes and their uses (2020-01-07),

2. 10301390 - Anti-IFNAR1 antibodies with reduced Fc ligand affinity (2019-05-28),

3. 10150800 - EGFR-binding modular recognition domains (2018-12-11),

4. 10087222 - Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides (2018-10-02),

5. 9988459 - Anti-IFNAR1 antibodies with reduced Fc ligand affinity (2018-06-05),

6. 9896505 - Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease (2018-02-20),

7. 9676833 - Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof (2017-06-13),

8. 8883992 - Humanized anti-CD19 antibodies (2014-11-11),

9. 8404236 - Method of identifying membrane Ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells (2013-03-26),

10. 8323653 - Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease (2012-12-04),

11. 8153131 - High affinity antibodies against HMGB1 and methods of use thereof (2012-04-10),

12. 8137670 - Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells (2012-03-20),

13. 8129130 - High affinity antibodies against HMGB1 and methods of use thereof (2012-03-06),

14. 7964706 - High affinity antibodies against HMGB1 and methods of use thereof (2011-06-21),

15. 7658921 - Molecules with extended half-lives, compositions and uses thereof (2010-02-09),

Title: Innovations and Achievements of Inventor Peter Kiener

Introduction

Peter Kiener, an accomplished inventor based in Potomac, MD, has made significant contributions to the field of biochemistry and molecular biology. With a total of 16 patents to his name, Kiener has focused on developing innovative technologies that enhance therapeutic options for various medical applications.

Latest Patents

Among his noteworthy inventions, Kiener's latest patents include "Multivalent and Monovalent Multispecific Complexes and Their Uses," which describe compositions containing scaffolds, such as antibodies, capable of supporting specific binding functionalities. This innovation provides valuable insights into the design and application of complex antibody structures. Additionally, he holds a patent for "Anti-IFNAR1 Antibodies with Reduced Fc Ligand Affinity," which details antibodies engineered to exhibit reduced affinity for Fc receptors, alongside methods for their production and use.

Career Highlights

Peter Kiener has worked with prominent companies in the biopharmaceutical industry, including MedImmune Limited and Zyngenia, Inc. Throughout his career, Kiener has focused on advancing antibody technologies, contributing to the development of groundbreaking therapies that address unmet medical needs.

Collaborations

During his professional journey, Kiener has collaborated with talented individuals such as Herren Wu and Anthony Coyle. Their collective efforts have been pivotal in driving forward the innovations in antibody design and utilization, establishing Kiener as a key figure in the research community.

Conclusion

Peter Kiener's work exemplifies the spirit of innovation and dedication to improving healthcare outcomes through scientific advancement. His patents and collaborations continue to pave the way for new therapeutic approaches, making a lasting impact in the world of biomedicine.

This text is generated by artificial intelligence and may not be accurate.